The Rx Savings Finder marketplace has already saved patients almost $70 millionRead more...
The company also sells drug-free products for preventing hair loss and regaining hair density
Androgenetic alopecia, more commonly known as male-pattern and female-pattern baldness, affects an estimated 50 million men and 30 million women in the US alone. Yet, despite those numbers, there's not much that can be done to help people who have this condition.
"There are only a few approved treatments on the market. Those treatments are ineffective for a lot of hair loss sufferers. Since hair loss causes are multifactorial, the clinical literature shows that combinations of active ingredients against hair loss show better efficacy and satisfactory hair growth results," Jean-Philippe Gravel, President and CEO of Triple Hair Group, told VatorNews.
Triple Hair is a Canadian biotechnology company that specializes in developing treatments for men and women suffering from alopecia, including prescription and over-the-counter treatments for hair regrowth. Now, the company is making it even easier for patients to access care with the launch of its asynchronous telehealth service, called Hair Loss Rx Consult.
To use Hair Loss Rx Consult, the patient fills out a platform questionnaire and then selects a consulting plan based on review time by a clinician. The company currently offers two plans: the Express, which cost $60 and allows a patient to obtain a diagnosis and treatment plan within three days, and Regular, which cost $30 and takes five days. After payment, the clinician will ask additional questions if needed before coming up with a diagnostic and a personalized treatment plan.
After the consultation, a prescription would then be sent to Triple Hair's partnered compounding pharmacy, which will contact the patient to fulfill the prescription, and then send it directly to their home.
"To facilitate the process of getting a rapid diagnostic and a treatment plan of topical solutions combining multiple active ingredients., the Hair Loss Rx Consult platform uses a similar approach to a traditional visit to a clinic," said Gravel.
"A consult starts a chat communication between the clinician and the patient with the goal of having a prescribed medication personalized to your hair loss situation. The interactive communication and the data are encrypted to ensure the highest standard of confidentiality."
The Hair Loss Rx Consult service, which is powered by technology from Oro Health, a provider of asynchronous medicine solutions for medical specialists, is currently available for most Canadian province citizens and should be available for US state residents next year.
In addition to its telehealth service, Triple Hair Group sells its drug-free patented products for preventing hair loss and regaining hair density in mild to moderate cases of alopecia under the brands RIZN and Plenty Natural for women.
"Triple Hair has tested multiple fixed-dose combinations of recognized ingredients for hair growth. The company has patented a formulation combining minoxidil, finasteride and latanoprost which has shown great results in comparison to each individual ingredient," Gravel explained, noting that, in a proof study, the triple combination showed moderate to dense hair growth in over 80% of the patients.
"The superior efficacy is due to the multiple modes of action done by the synergy of the three ingredients."
Triple Hair is currently raising funding to initiate and complete its phase III trial in humans for its hair growth drug candidate TH07 at the end of 2023.
"We’ve just launched the platform and we are quite happy with the level of interest and number of prescriptions thus far. In 2023, we anticipate having thousands of users considering that over 20% of the population is suffering from hair loss," Gravel said.
(Image source: hairlossrxconsult.ca)
Support VatorNews by Donating
Read more from our "Trends and news" series
The company works with pharma and biotech to help with drug developmentRead more...
The company plans to open clinics in New Jersey, Connecticut, and Maryland next yearRead more...